Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells

Science

Volumn 279, Issue 5357, 1998, Pages 1737-1740

  Groh, Veronika ^a   Steinle, Alexander ^a   Bauer, Stefan ^a   Spies, Thomas ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN VARIABLE REGION; INTESTINE EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; STRESS; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CARRIER PROTEINS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; HEAT; HEAT-SHOCK RESPONSE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOPHENOTYPING; INTESTINAL MUCOSA; LIGANDS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032513388     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5357.1737     Document Type: Article

References (56)

1. S. Porcelli, M. B. Brenner, H. Band, Immunol. Rev. 120, 137 (1991).
2. J. Holoshitz et al., Int. Immunol. 5, 1437 (1993); B. C. Weintraub, M. R. Jackson, S. M. Hedrick, J. Immunol. 153, 3051 (1994); C. T. Morita et al., Immunity 3, 495 (1995).
3. J. Holoshitz et al., Int. Immunol. 5, 1437 (1993); B. C. Weintraub, M. R. Jackson, S. M. Hedrick, J. Immunol. 153, 3051 (1994); C. T. Morita et al., Immunity 3, 495 (1995).
4. J. Holoshitz et al., Int. Immunol. 5, 1437 (1993); B. C. Weintraub, M. R. Jackson, S. M. Hedrick, J. Immunol. 153, 3051 (1994); C. T. Morita et al., Immunity 3, 495 (1995).
5. E. P. Rock, P. R. Sibbald, M. M. Davis, Y.-h. Chien, J. Exp. Med. 179, 323 (1994); H. Schild et al., Cell 76, 29 (1994).
6. E. P. Rock, P. R. Sibbald, M. M. Davis, Y.-h. Chien, J. Exp. Med. 179, 323 (1994); H. Schild et al., Cell 76, 29 (1994).
7. R. L. Modlin et al. ,Nature 339, 544 (1989); D. Kabelitz, A. Bender, S. Schondelmeier, S. Schoel, S. H. E. Kaufmann, J. Exp. Med. 171, 667 (1990); G. De Libero et al., ibid. 173, 1311 (1991); J. F. Bukowski et al., J. Immunol. 154, 998 (1995); Y. Tanaka et al., Nature 375, 155 (1995).
8. R. L. Modlin et al. ,Nature 339, 544 (1989); D. Kabelitz, A. Bender, S. Schondelmeier, S. Schoel, S. H. E. Kaufmann, J. Exp. Med. 171, 667 (1990); G. De Libero et al., ibid. 173, 1311 (1991); J. F. Bukowski et al., J. Immunol. 154, 998 (1995); Y. Tanaka et al., Nature 375, 155 (1995).
9. R. L. Modlin et al. ,Nature 339, 544 (1989); D. Kabelitz, A. Bender, S. Schondelmeier, S. Schoel, S. H. E. Kaufmann, J. Exp. Med. 171, 667 (1990); G. De Libero et al., ibid. 173, 1311 (1991); J. F. Bukowski et al., J. Immunol. 154, 998 (1995); Y. Tanaka et al., Nature 375, 155 (1995).
10. R. L. Modlin et al. ,Nature 339, 544 (1989); D. Kabelitz, A. Bender, S. Schondelmeier, S. Schoel, S. H. E. Kaufmann, J. Exp. Med. 171, 667 (1990); G. De Libero et al., ibid. 173, 1311 (1991); J. F. Bukowski et al., J. Immunol. 154, 998 (1995); Y. Tanaka et al., Nature 375, 155 (1995).
11. R. L. Modlin et al. ,Nature 339, 544 (1989); D. Kabelitz, A. Bender, S. Schondelmeier, S. Schoel, S. H. E. Kaufmann, J. Exp. Med. 171, 667 (1990); G. De Libero et al., ibid. 173, 1311 (1991); J. F. Bukowski et al., J. Immunol. 154, 998 (1995); Y. Tanaka et al., Nature 375, 155 (1995).
12. F. Koning, M. Knot, F. Wassenaar, P. van den Elsen, Eur. J. Immunol. 19, 2099 (1989); J. Spencer, P. G. Isaacson, T. C. Diss, T. T. MacDonald, ibid., p. 1335; K. Deusch et al., ibid. 21, 1053 (1991); C. Lundqvist, V. Baranov, S. Hammarstrom, L. Athlein, M.-L. Hammarstrom, Int. Immunol. 7, 1473 (1995).
13. F. Koning, M. Knot, F. Wassenaar, P. van den Elsen, Eur. J. Immunol. 19, 2099 (1989); J. Spencer, P. G. Isaacson, T. C. Diss, T. T. MacDonald, ibid., p. 1335; K. Deusch et al., ibid. 21, 1053 (1991); C. Lundqvist, V. Baranov, S. Hammarstrom, L. Athlein, M.-L. Hammarstrom, Int. Immunol. 7, 1473 (1995).
14. F. Koning, M. Knot, F. Wassenaar, P. van den Elsen, Eur. J. Immunol. 19, 2099 (1989); J. Spencer, P. G. Isaacson, T. C. Diss, T. T. MacDonald, ibid., p. 1335; K. Deusch et al., ibid. 21, 1053 (1991); C. Lundqvist, V. Baranov, S. Hammarstrom, L. Athlein, M.-L. Hammarstrom, Int. Immunol. 7, 1473 (1995).
15. F. Koning, M. Knot, F. Wassenaar, P. van den Elsen, Eur. J. Immunol. 19, 2099 (1989); J. Spencer, P. G. Isaacson, T. C. Diss, T. T. MacDonald, ibid., p. 1335; K. Deusch et al., ibid. 21, 1053 (1991); C. Lundqvist, V. Baranov, S. Hammarstrom, L. Athlein, M.-L. Hammarstrom, Int. Immunol. 7, 1473 (1995).
16. Y. Chowers, W. Holtmeier, J. Harwood, E. Morzycka-Wroblewska, M. F. Kagnoff, J. Exp. Med. 180, 183 (1994); W. Holtmeier, T. Witthoft, A. Hennemann, H. S. Winter, M. F. Kagnoff, J. Immunol. 158, 5632 (1997).
17. Y. Chowers, W. Holtmeier, J. Harwood, E. Morzycka-Wroblewska, M. F. Kagnoff, J. Exp. Med. 180, 183 (1994); W. Holtmeier, T. Witthoft, A. Hennemann, H. S. Winter, M. F. Kagnoff, J. Immunol. 158, 5632 (1997).
18. D. M. Asarnow et al., Cell 55, 837 (1988); C. A. Janeway Jr., B. Jones, A. Hayday, Immunol. Today 9, 73 (1988); W. L. Havran, Y.-H. Chien, J. P. Allison, Science 252, 1430 (1991); R. Boismenu and W. L. Havran, ibid. 266, 1253 (1994).
19. D. M. Asarnow et al., Cell 55, 837 (1988); C. A. Janeway Jr., B. Jones, A. Hayday, Immunol. Today 9, 73 (1988); W. L. Havran, Y.-H. Chien, J. P. Allison, Science 252, 1430 (1991); R. Boismenu and W. L. Havran, ibid. 266, 1253 (1994).
20. D. M. Asarnow et al., Cell 55, 837 (1988); C. A. Janeway Jr., B. Jones, A. Hayday, Immunol. Today 9, 73 (1988); W. L. Havran, Y.-H. Chien, J. P. Allison, Science 252, 1430 (1991); R. Boismenu and W. L. Havran, ibid. 266, 1253 (1994).
21. D. M. Asarnow et al., Cell 55, 837 (1988); C. A. Janeway Jr., B. Jones, A. Hayday, Immunol. Today 9, 73 (1988); W. L. Havran, Y.-H. Chien, J. P. Allison, Science 252, 1430 (1991); R. Boismenu and W. L. Havran, ibid. 266, 1253 (1994).
22. V. Groh et al., Proc. Natl. Acad. Sci. U.S.A. 93, 12445 (1996).
23. S. Bahram, M. Bresnahan, D. E. Geraghty, T. Spies, ibid. 91, 6259 (1994).
24. + as shown by staining with mAb CD103 (Immunotech). After another 3 weeks, T cells were grown in the additional presence of irradiated allogeneic peripheral blood mononuclear cells. T cell clones from the β1A and β1B lines were derived after the first week of culture by limiting dilution-plating and expanded for at least 3 weeks before functional testing.
25. + as shown by staining with mAb CD103 (Immunotech). After another 3 weeks, T cells were grown in the additional presence of irradiated allogeneic peripheral blood mononuclear cells. T cell clones from the β1A and β1B lines were derived after the first week of culture by limiting dilution-plating and expanded for at least 3 weeks before functional testing.
26. + as shown by staining with mAb CD103 (Immunotech). After another 3 weeks, T cells were grown in the additional presence of irradiated allogeneic peripheral blood mononuclear cells. T cell clones from the β1A and β1B lines were derived after the first week of culture by limiting dilution-plating and expanded for at least 3 weeks before functional testing.
27. + as shown by staining with mAb CD103 (Immunotech). After another 3 weeks, T cells were grown in the additional presence of irradiated allogeneic peripheral blood mononuclear cells. T cell clones from the β1A and β1B lines were derived after the first week of culture by limiting dilution-plating and expanded for at least 3 weeks before functional testing.
28. + as shown by staining with mAb CD103 (Immunotech). After another 3 weeks, T cells were grown in the additional presence of irradiated allogeneic peripheral blood mononuclear cells. T cell clones from the β1A and β1B lines were derived after the first week of culture by limiting dilution-plating and expanded for at least 3 weeks before functional testing.
29. + as shown by staining with mAb CD103 (Immunotech). After another 3 weeks, T cells were grown in the additional presence of irradiated allogeneic peripheral blood mononuclear cells. T cell clones from the β1A and β1B lines were derived after the first week of culture by limiting dilution-plating and expanded for at least 3 weeks before functional testing.
30. The mAb 6D4 was generated by immunization of RBF/DnJ mice (Jackson Laboratories) with mouse LTK-MICA transfectants as described (8) and identified by screenings of hybridoma supernatants by indirect immunofluoresence stainings and flow cytometry of C1R, C1R-MICA, and C1R-MICB transfectants (13). This mAb was subcloned twice and is of the immunoglobulin G1 (IgGI) isotype.
31. V. Groh et al., data not shown.
32. 2M cells [B. Sadasivan, P. J. Lehner, B. Ortmann, T. Spies, P. Cresswell, Immunity 5, 103 (1996)] with MICA cDNA (9) in RSV.5neo or in pREP8Δ (8) [D. Arnold et al., Nature 360, 171 (1992)], and of C1R cells with MICB cDNA [S. Bahram and T. Spies, Immunogenetics 43, 230 (1996)] in RSV.5neo, were done as described [A. G. Grandea III, M. J. Androlewicz, R. S. Athwal, D. E. Geraghty, T. Spies, Science 270, 105 (1995)]. Stable transfectant isolates had large amounts of surface MICA or MICB, as shown by indirect immunofluorescence stainings with mAb 2C10 or 6D4 and flow cytometry (8, 11).
33. 2M cells [B. Sadasivan, P. J. Lehner, B. Ortmann, T. Spies, P. Cresswell, Immunity 5, 103 (1996)] with MICA cDNA (9) in RSV.5neo or in pREP8Δ (8) [D. Arnold et al., Nature 360, 171 (1992)], and of C1R cells with MICB cDNA [S. Bahram and T. Spies, Immunogenetics 43, 230 (1996)] in RSV.5neo, were done as described [A. G. Grandea III, M. J. Androlewicz, R. S. Athwal, D. E. Geraghty, T. Spies, Science 270, 105 (1995)]. Stable transfectant isolates had large amounts of surface MICA or MICB, as shown by indirect immunofluorescence stainings with mAb 2C10 or 6D4 and flow cytometry (8, 11).
34. 2M cells [B. Sadasivan, P. J. Lehner, B. Ortmann, T. Spies, P. Cresswell, Immunity 5, 103 (1996)] with MICA cDNA (9) in RSV.5neo or in pREP8Δ (8) [D. Arnold et al., Nature 360, 171 (1992)], and of C1R cells with MICB cDNA [S. Bahram and T. Spies, Immunogenetics 43, 230 (1996)] in RSV.5neo, were done as described [A. G. Grandea III, M. J. Androlewicz, R. S. Athwal, D. E. Geraghty, T. Spies, Science 270, 105 (1995)]. Stable transfectant isolates had large amounts of surface MICA or MICB, as shown by indirect immunofluorescence stainings with mAb 2C10 or 6D4 and flow cytometry (8, 11).
35. 2M cells [B. Sadasivan, P. J. Lehner, B. Ortmann, T. Spies, P. Cresswell, Immunity 5, 103 (1996)] with MICA cDNA (9) in RSV.5neo or in pREP8Δ (8) [D. Arnold et al., Nature 360, 171 (1992)], and of C1R cells with MICB cDNA [S. Bahram and T. Spies, Immunogenetics 43, 230 (1996)] in RSV.5neo, were done as described [A. G. Grandea III, M. J. Androlewicz, R. S. Athwal, D. E. Geraghty, T. Spies, Science 270, 105 (1995)]. Stable transfectant isolates had large amounts of surface MICA or MICB, as shown by indirect immunofluorescence stainings with mAb 2C10 or 6D4 and flow cytometry (8, 11).
36. N. Cerf-Bensussan et al., Eur. J. Immunol. 17, 1279 (1987); K. L. Cepek et al., Nature 372, 190 (1994).
37. N. Cerf-Bensussan et al., Eur. J. Immunol. 17, 1279 (1987); K. L. Cepek et al., Nature 372, 190 (1994).
38. 5.1Cr]sodium chromate and washing. Adherent target cells were harvested with nonenzymatic cell dissociation solution (Sigma). Effectors were added at the indicated ratios and briefly centrifuged, and released radioactivity was determined after 4 hours at 37°C by means of Luma Plates and a TopCount microplate scintillation counter (Packard). Specific lysis (expressed as a percentage) was calculated using the standard formula [(experimental - spontaneous release/total - spontaneous release) × 100]. Data in Figs. 1 and 2 are the mean of triplicate experiments with usually less than ±5% deviation. All experiments were repeated at least once and in most cases several times. For blocking with mAb, labeled target cells were preincubated for 30 min with saturating amounts of 2C10, 6D4, or W6/32 ascites before exposure to T cells. TCR Vγ1 mAb δTCS1 (10) or control IgG1 was added at 10 μg/ml to T cells 30 min before the addition of labeled targets
39. B. Arce-Gomez, E. A. Jones, C. J. Barnstable, E. Solomon, W. F. Bodmer, Tissue Antigens 11, 96 (1978).
40. E. Mellins, S. Kempin, L. Smith, T. Monji, D. Pious, J. Exp. Med. 174, 1607 (1991).
41. I. A. York and K. L. Rock, Annu. Rev. Immunol. 14, 369 (1996); J. O. Koopmann, G. J. Hämmerling, F. Momburg, Curr. Opin. Immunol. 9, 80 (1997).
42. I. A. York and K. L. Rock, Annu. Rev. Immunol. 14, 369 (1996); J. O. Koopmann, G. J. Hämmerling, F. Momburg, Curr. Opin. Immunol. 9, 80 (1997).
43. Target cells were exposed to 10 or 50 μM lactacystin (Calbiochem) for 2 hours before labeling and subsequent testing with the δ1B T cells [G. Fenteany et al., Science 268, 726 (1995)].
44. 3H-labeled amino acids (Code TRK440; Amersham) and proteins solubilized in 2 ml of NP-40 lysis buffer in the presence of protease inhibitors. After preclearing with protein A-Sepharose (Pharmacia), MICA and MHC class I (C1R cells express only HLA-C) were each precipitated from half of the lysate using ascites of mAb 2C10 and W6/32 (21), respectively. Washed immunoprecipitates were incubated in 0.2 ml of 1 M acetic acid for 15 min and fractionated by gel filtration using a Biogel P10 column (Bio-Rad; equilibrated with 1 M acetic acid, 1% bovine serum albumin, and 0.1% NP-40). Fractions (0.5 ml) were collected and radioactivity was counted.
45. P. Parham, C. J. Barnstable, W. F. Bodmer, J. Immunol. 123, 342 (1979).
46. Cell lines DLD-1, Lovo, HCT116, and HUTU-80 were from the American Type Culture Collection (ATCC).
47. K. L. Milarski and R. I. Morimoto, Proc. Natl. Acad. Sci. U.S.A. 83, 9517 (1986); C. Kanei-Ishii, J. Tanikawa, A. Nakai, R. I. Morimoto, S. Ishii, Science 277, 246 (1997).
48. K. L. Milarski and R. I. Morimoto, Proc. Natl. Acad. Sci. U.S.A. 83, 9517 (1986); C. Kanei-Ishii, J. Tanikawa, A. Nakai, R. I. Morimoto, S. Ishii, Science 277, 246 (1997).
49. 32P)deoxycytidine triphosphate-labeled DNA probes for MICA, HLA-B, and hsp70 as described (8). For surface staining with mAb and cytotoxicity assays, cells were harvested 12 to 16 hours after heat shock induction with nonenzymatic cell dissociation solution (Sigma).
50. γ2 (5′-AAGTCGACTATTGGTATCGAGAGAGACC-3′), Cγ [biotin-(5′-CCGAATTCGTATGTTCCAGCCTTCTGGA-3′)], Vδ1 (5′-CCGTCGACGTCAACTTCAAGAAAGCAGC-3′), and Cδ [biotin-(5′-GTAGAATTCCTTCACCAGAC-3′)]. PCR cycles included 30 s at 95°C, 20 s at 56°C, and 60 s at 72°C. Alkali-denatured DNA strands were separated with streptavidin-coupled magnetic beads (M-280; Dynal) and single-stranded DNAs were sequenced. The GenBank accession numbers of the five γ and five 8 chain sequences (in order from 1 to 5) are AF025412 to AF025416 and AF025417 to AF025421, respectively.
51. S. Hata et al., Science 240, 1541 (1988); E. Y. Loh, S. Cwirla, A. T. Serafini, J. H. Phillips, L. L. Lanier, Proc. Natl. Acad. Sci. U.S.A. 85, 9714 (1988).
52. S. Hata et al., Science 240, 1541 (1988); E. Y. Loh, S. Cwirla, A. T. Serafini, J. H. Phillips, L. L. Lanier, Proc. Natl. Acad. Sci. U.S.A. 85, 9714 (1988).
53. M. J. Maeurer et al., J. Exp. Med. 183, 1681 (1996).
54. N. Fodil et al., Immunogenetics 44, 351 (1996).
55. We tested C1R cDNA transfectants expressing MICA alleles 1, 4, and 5 (73, 28).
56. We thank K. Grabstein and H. Secrist for the tumor-derived lymphocytes, N. Vita for rhIL-7, P. Cresswell and D. Pious for cell lines, H. Marquardt and W.-C. Wang for guidance in the biochemical procedure, and S. Riddell and A. Grandea for helpful comments on the manuscript. A.S. and S.B. were supported by fellowships from the Deutsche Forschungsgemeinschaft. Supported by NIH grants RO1 Al30581 and PO1 CA18221.